[Transgenic plants].
Advances in molecular genetics and recombinant DNA technology have revolutionized our understanding of the pathogenesis as well as the diagnosis, therapy and prevention of human diseases. Similar developments characterize plant biotechnology with the production of plant derived biomedical as well as health products. Apart from the fundamentals of molecular plant genetics, the production of transgenic plants as well as the clinical relevance, benefits, limitations and potential problems of plant biotechnology will be reviewed in some detail. It is a particular challenge to physicians in an increasingly informed environment to be informed about the new developments in molecular biology and recombinant DNA technology and to have a qualified opinion about their clinical relevance.
Blum
H E
HE
Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizin II (Gastroenterologie, Hepatologie, Endokrinologie). heblum@ukl.uni-freiburg.de
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000941:Antigens / Q000276:immunology; D001709:Biotechnology; D004274:DNA, Recombinant; D003922:Diabetes Mellitus, Type 1 / Q000517:prevention & control; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D006801:Humans; D051379:Mice; D008967:Molecular Biology; D030821:Plants, Genetically Modified / Q000235:genetics / Q000276:immunology; D012231:Rhizobium; D012307:Risk Factors; D012449:Safety; D011198:Solanum tuberosum / Q000235:genetics
D000906:Antibodies; D000941:Antigens; D004274:DNA, Recombinant